Ravn P - Search Results

1

Depression: a major, unrecognized risk factor for osteoporosis?

Cizza G, Ravn P, Chrousos GP, Gold PW. Cizza G, et al. Among authors: ravn p. Trends Endocrinol Metab. 2001 Jul;12(5):198-203. doi: 10.1016/s1043-2760(01)00407-6. Trends Endocrinol Metab. 2001. PMID: 11397644 Review.

2

Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.

Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C. Ravn P, et al. J Clin Endocrinol Metab. 1999 Jul;84(7):2363-8. doi: 10.1210/jcem.84.7.5847. J Clin Endocrinol Metab. 1999. PMID: 10404804 Clinical Trial.

3

Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group.

Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD, McClung M, Hosking D, Yates AJ, Christiansen C. Ravn P, et al. J Bone Miner Res. 1999 Sep;14(9):1622-7. doi: 10.1359/jbmr.1999.14.9.1622. J Bone Miner Res. 1999. PMID: 10469292 Free article. Clinical Trial.

4

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G. Ravn P, et al. Ann Intern Med. 1999 Dec 21;131(12):935-42. doi: 10.7326/0003-4819-131-12-199912210-00005. Ann Intern Med. 1999. PMID: 10610644 Clinical Trial.

5

Evidence that increased calcium intake does not prevent early postmenopausal bone loss.

Hosking DJ, Ross PD, Thompson DE, Wasnich RD, McClung M, Bjarnason NH, Ravn P, Cizza G, Daley M, Yates AJ. Hosking DJ, et al. Among authors: ravn p. Clin Ther. 1998 Sep-Oct;20(5):933-44. doi: 10.1016/s0149-2918(98)80075-1. Clin Ther. 1998. PMID: 9829445 Clinical Trial.

6

Insulin-like growth factors I and II in healthy women with and without established osteoporosis.

Ravn P, Overgaard K, Spencer EM, Christiansen C. Ravn P, et al. Eur J Endocrinol. 1995 Mar;132(3):313-9. doi: 10.1530/eje.0.1320313. Eur J Endocrinol. 1995. PMID: 7889180 Clinical Trial.

7

Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group.

Ravn P, Weiss SR, Rodriguez-Portales JA, McClung MR, Wasnich RD, Gilchrist NL, Sambrook P, Fogelman I, Krupa D, Yates AJ, Daifotis A, Fuleihan GE. Ravn P, et al. J Clin Endocrinol Metab. 2000 Apr;85(4):1492-7. doi: 10.1210/jcem.85.4.6549. J Clin Endocrinol Metab. 2000. PMID: 10770187 Clinical Trial.

8

A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.

Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY. Clemmesen B, et al. Among authors: ravn p. Osteoporos Int. 1997;7(5):488-95. doi: 10.1007/pl00004152. Osteoporos Int. 1997. PMID: 9425508 Clinical Trial.

9

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P. Ravn P. Dan Med Bull. 2002 Feb;49(1):1-18. Dan Med Bull. 2002. PMID: 11894721 Review.

10

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study.

McClung MR, Wasnich RD, Hosking DJ, Christiansen C, Ravn P, Wu M, Mantz AM, Yates J, Ross PD, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study. McClung MR, et al. Among authors: ravn p. J Clin Endocrinol Metab. 2004 Oct;89(10):4879-85. doi: 10.1210/jc.2003-031672. J Clin Endocrinol Metab. 2004. PMID: 15472179 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters